FI120499B - Menetelmiä, jotka liittyvät Grb3-3-geeniin tai sen variantteihin - Google Patents

Menetelmiä, jotka liittyvät Grb3-3-geeniin tai sen variantteihin Download PDF

Info

Publication number
FI120499B
FI120499B FI961202A FI961202A FI120499B FI 120499 B FI120499 B FI 120499B FI 961202 A FI961202 A FI 961202A FI 961202 A FI961202 A FI 961202A FI 120499 B FI120499 B FI 120499B
Authority
FI
Finland
Prior art keywords
grb3
sequence
vector
grb2
gene
Prior art date
Application number
FI961202A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI961202A (fi
FI961202A0 (fi
Inventor
Bruno Tocque
Fabien Schweighoffer
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of FI961202A publication Critical patent/FI961202A/fi
Publication of FI961202A0 publication Critical patent/FI961202A0/fi
Application granted granted Critical
Publication of FI120499B publication Critical patent/FI120499B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
FI961202A 1993-09-15 1996-03-14 Menetelmiä, jotka liittyvät Grb3-3-geeniin tai sen variantteihin FI120499B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9310971 1993-09-15
FR9310971A FR2710074B1 (fr) 1993-09-15 1993-09-15 Gène GRB3-3, ses variants et leurs utilisations.
FR9400542 1994-05-09
PCT/FR1994/000542 WO1995007981A1 (fr) 1993-09-15 1994-05-09 Gene grb3-3, ses variants et leurs utilisations

Publications (3)

Publication Number Publication Date
FI961202A FI961202A (fi) 1996-03-14
FI961202A0 FI961202A0 (fi) 1996-03-14
FI120499B true FI120499B (fi) 2009-11-13

Family

ID=9450882

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961202A FI120499B (fi) 1993-09-15 1996-03-14 Menetelmiä, jotka liittyvät Grb3-3-geeniin tai sen variantteihin

Country Status (27)

Country Link
US (2) USRE37952E1 (hu)
EP (1) EP0719328B1 (hu)
JP (1) JP3794697B2 (hu)
KR (1) KR100330477B1 (hu)
CN (1) CN1098930C (hu)
AT (1) ATE196926T1 (hu)
AU (1) AU698819B2 (hu)
BR (1) BR9407693A (hu)
CA (1) CA2169938A1 (hu)
CZ (1) CZ288882B6 (hu)
DE (1) DE69426121T2 (hu)
DK (1) DK0719328T3 (hu)
ES (1) ES2152313T3 (hu)
FI (1) FI120499B (hu)
FR (1) FR2710074B1 (hu)
GR (1) GR3034600T3 (hu)
HU (1) HU221516B (hu)
IL (2) IL126756A (hu)
NO (1) NO319144B1 (hu)
NZ (1) NZ266162A (hu)
PL (1) PL178402B1 (hu)
PT (1) PT719328E (hu)
RU (1) RU2159815C2 (hu)
SK (1) SK281123B6 (hu)
UA (1) UA46715C2 (hu)
WO (1) WO1995007981A1 (hu)
ZA (1) ZA947059B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US6171800B1 (en) 1995-06-07 2001-01-09 Biogen, Inc. Method of making and binding CAIP polypeptides
US5837844A (en) * 1995-06-07 1998-11-17 Biogen, Inc. CAIP-like gene family
US6423824B1 (en) 1995-06-07 2002-07-23 Biogen, Inc. CAIP-like gene family
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
WO1997049808A1 (en) * 1996-06-27 1997-12-31 Biogen, Inc. The caip-like gene family
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP0998945A1 (en) * 1998-09-30 2000-05-10 Transgene S.A. Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
NZ553687A (en) 2000-03-30 2010-03-26 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
EP1873259B1 (en) 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
WO2003061386A1 (en) * 2002-01-03 2003-07-31 Board Of Regents, The University Of Texas System Wt1 antisense oligos for the inhibition of breast cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667803B2 (en) * 1991-01-18 1996-04-18 New York University A receptor tyrosine kinase target protein cDNA cloning method and hGRB proteins
AU5136093A (en) * 1992-09-25 1994-04-26 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof

Also Published As

Publication number Publication date
PL178402B1 (pl) 2000-04-28
EP0719328B1 (fr) 2000-10-11
ES2152313T3 (es) 2001-02-01
ZA947059B (en) 1995-05-18
JP3794697B2 (ja) 2006-07-05
PL313445A1 (en) 1996-07-08
CN1098930C (zh) 2003-01-15
CZ75896A3 (en) 1996-06-12
IL126756A (en) 2006-06-11
AU698819B2 (en) 1998-11-05
RU2159815C2 (ru) 2000-11-27
DK0719328T3 (da) 2000-11-13
CA2169938A1 (fr) 1995-03-23
USRE37952E1 (en) 2002-12-31
FR2710074B1 (fr) 1995-12-08
HU221516B (hu) 2002-11-28
NO960965D0 (no) 1996-03-08
IL110942A0 (en) 1994-11-28
FI961202A (fi) 1996-03-14
JPH09502357A (ja) 1997-03-11
KR100330477B1 (ko) 2002-12-02
FR2710074A1 (fr) 1995-03-24
PT719328E (pt) 2001-02-28
DE69426121T2 (de) 2001-05-31
NO319144B1 (no) 2005-06-27
BR9407693A (pt) 1997-02-04
WO1995007981A1 (fr) 1995-03-23
CZ288882B6 (cs) 2001-09-12
HU9600668D0 (en) 1996-05-28
ATE196926T1 (de) 2000-10-15
NZ266162A (en) 1997-11-24
SK281123B6 (sk) 2000-12-11
EP0719328A1 (fr) 1996-07-03
SK34596A3 (en) 1996-07-03
CN1133064A (zh) 1996-10-09
UA46715C2 (uk) 2002-06-17
FI961202A0 (fi) 1996-03-14
GR3034600T3 (en) 2001-01-31
DE69426121D1 (de) 2000-11-16
IL110942A (en) 2001-12-23
US5831048A (en) 1998-11-03
NO960965L (no) 1996-03-08
AU6724794A (en) 1995-04-03
HUT74273A (en) 1996-11-28

Similar Documents

Publication Publication Date Title
FI120499B (fi) Menetelmiä, jotka liittyvät Grb3-3-geeniin tai sen variantteihin
CA2148258A1 (en) Transcription factor dp-1
US6077686A (en) Shc proteins
WO1997032020A9 (en) Shc proteins
WO2000017345A1 (fr) Gene ly6h
US20060228365A1 (en) Protein and gene involved in myocyte differentiation
KR20070011892A (ko) Ｍｓｘ1 단백질 또는 이를 코딩하는 유전자를유효성분으로 포함하는 세포사멸유도제
AU722973B2 (en) Grb3-3 gene, variants and uses thereof
EP0846761A1 (en) A novel transcription factor expressed in cycling cells, nucleic acid molecules encoding said transcription factor and its promoter region and uses thereof
JPH10512145A (ja) ヒトゲラニルゲラニルピロリン酸シンセターゼ
CZ291533B6 (cs) Deriváty proteinu p62, nukleové kyseliny kódující tyto deriváty a farmaceutické kompozice, které je obsahují
KR100509398B1 (ko) 세포침투성 티에이티-박테리아 사이토신 디아미네이즈융합단백질 및 그 용도
JP2000083672A (ja) アポトーシス関連タンパク質
NO315895B1 (no) Farmasöytisk preparat for kontroll av cellesyklusutvikling, fremstilling avdette for regulering av cellesyklusutvikling i en celle sommangler et funksjonelt retinoblastomtumorsuppressorprotein, samt fremgangsmåte forkontroll av cellesyklusutv
JPH11507208A (ja) アポトーシス遺伝子１のヒトインヒビター

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AVENTIS PHARMA S.A.

FG Patent granted

Ref document number: 120499

Country of ref document: FI